Structured evidence table for Prebiotics Constipation Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Prebiotics Constipation Randomized Trial | Evidence has accumulated in recent years that gut microbiota dysbiosis may be an early event in PD, driving neuroinflammation and neurodegeneration through the gut-brain axis (,). | 3 | Wang Wanhong (2026) | The gut microbiota-short-chain fatty acid-inflammation axis in Parkinson's disease motor dysfunction: mechanisms and future of dietary interventions |
| Prebiotics Constipation Randomized Trial | 7 8 9 10 11 12 10 Studies have shown that fecal SCFA levels are significantly reduced in PD patients, while plasma acetate levels are abnormally elevated-a paradoxical finding possibly related to intestinal barrier disruption and systemic inflammation (,). | 3 | Wang Wanhong (2026) | The gut microbiota-short-chain fatty acid-inflammation axis in Parkinson's disease motor dysfunction: mechanisms and future of dietary interventions |
| Prebiotics Constipation Randomized Trial | For example, butyrate, an important SCFA, exerts neuroprotective effects by inhibiting histone deacetylases (HDACs) and activating G protein-coupled receptors (e.g., GPR41/43), but its levels are markedly reduced in PD patients (). | 3 | Wang Wanhong (2026) | The gut microbiota-short-chain fatty acid-inflammation axis in Parkinson's disease motor dysfunction: mechanisms and future of dietary interventions |
| Prebiotics Constipation Randomized Trial | Its pathology involves progressive loss of dopaminergic neurons in the substantia nigra and abnormal α-synuclein aggregation, leading to typical motor symptoms such as tremor, rigidity, and bradykinesia (,). | 3 | Wang Wanhong (2026) | The gut microbiota-short-chain fatty acid-inflammation axis in Parkinson's disease motor dysfunction: mechanisms and future of dietary interventions |
| Prebiotics Constipation Randomized Trial | Although microbiota-based interventions show potential therapeutic value in selected patients, current evidence is limited by substantial heterogeneity in study design, small sample sizes, inconsistent microbiome signatures, and limited long-term safety data. | 4 | Chen Y (2026) | Gut microbiota and constipation: from causal evidence to therapeutic strategies-a state-of-the-art narrative review. |
| Prebiotics Constipation Randomized Trial | High-quality evidence from large, well-designed RCTs is lacking for most interventions, and findings from low-certainty studies (e.g., conference abstracts, animal experiments, small uncontrolled trials) should be interpreted as preliminary and hypothesis-generating rather than conclusive. | 4 | Chen Y (2026) | Gut microbiota and constipation: from causal evidence to therapeutic strategies-a state-of-the-art narrative review. |
| Prebiotics Constipation Randomized Trial | Constipation is a common functional disorder of the gastrointestinal tract with a global prevalence of approximately 10-20%, which seriously affects patients' quality of life and imposes a heavy socioeconomic burden. | 4 | Chen Y (2026) | Gut microbiota and constipation: from causal evidence to therapeutic strategies-a state-of-the-art narrative review. |
| Prebiotics Constipation Randomized Trial | In recent years, the role of the gut microbiota in the pathogenesis of constipation has received increasing attention, particularly in the context of the brain-gut axis theory. | 4 | Chen Y (2026) | Gut microbiota and constipation: from causal evidence to therapeutic strategies-a state-of-the-art narrative review. |
Source documents